BackQ/C Technologies Overview

Q/C Technologies EBIT

Q/C Technologies's EBIT is $-11M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.61M
↓ 92.92% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$10.97M
↓ 2.91% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Q/C Technologies (QCLS) FAQ

The latest EBIT for QCLS is $-11M as of June 2026. That compares with $-11M in the prior-year period — down 2.9% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Q/C Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, QCLS's EBIT moved from $-11M to $-11M — a 2.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Q/C Technologies's operating scale or balance-sheet position.

Against Healthcare companies, QCLS currently prints $-11M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Q/C Technologies's growth, margins, and balance sheet.

A EBIT figure of $-11M for QCLS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting QCLS's EBIT ($-11M), review year-over-year change from $-11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.